‘PARP’ing fibrosis: repurposing poly (ADP ribose) polymerase (PARP) inhibitors-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

‘PARP’ing fibrosis: repurposing poly (ADP ribose) polymerase (PARP) inhibitors

Published:2020-07 Issue:7 Volume:25 Page:1253-1261
ISSN:1359-6446
Container-title:Drug Discovery Today
language:en
Short-container-title:Drug Discovery Today

Author:

Rao Pooja Dhileepkumar^ORCID,Sankrityayan Himanshu,Srivastava Anjali,Kulkarni Yogesh A.,Mulay Shrikant R.^ORCID,Gaikwad Anil Bhanudas^ORCID

Funder

Science and Engineering Research Board- Department of Science and Technology, Government of India

Department of Biotechnology, Government of India

Publisher

Elsevier BV

Subject

Drug Discovery,Pharmacology

Reference82 articles.

1. Inflammation and fibrosis;Mack;Matrix Biol.,2018

2. Drugs and targets in fibrosis;Li;Front. Pharmacol.,2017

3. Decoding fibrosis: mechanisms and translational aspects;Schaefer;Matrix Biol.,2018

4. Resolution of organ fibrosis;Jun;J. Clin. Invest.,2018

5. Fibrosis—a common pathway to organ injury and failure;Rockey;N. Engl. J. Med.,2015

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cell death induced by acute renal injury: a perspective on the contributions of accidental and programmed cell death;American Journal of Physiology-Renal Physiology;2024-07-01

2. Hyperoside attenuates carbon tetrachloride-induced hepatic fibrosis via the poly(ADP-ribose)polymerase-1-high mobility group protein 1 pathway;European Journal of Pharmacology;2023-12

3. Dihydrokaempferol attenuates CCl4-induced hepatic fibrosis by inhibiting PARP-1 to affect multiple downstream pathways and cytokines;Toxicology and Applied Pharmacology;2023-04

4. Established and Emerging Cancer Therapies and Cardiovascular System: Focus on Hypertension—Mechanisms and Mitigation;Hypertension;2023-04

5. Predictive investigation of idiopathic pulmonary fibrosis subtypes based on cellular senescence-related genes for disease treatment and management;Frontiers in Genetics;2023-03-24

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3